Biocryst Pharmaceuticals Inc Financials
Biocryst Pharmaceuticals Inc (BCRX) reported $874.8M in revenue for fiscal year 2025, up 94.1% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Commercial scale finally outran the cost base, turning a high-gross-margin model into cash that could erase debt.
Between FY2024 and FY2025, revenue nearly doubled while SG&A plus R&D grew far more slowly, so the business crossed a fixed-cost absorption threshold: operating margin swung from-0.6% to39.0% . Because net income reached$263.9M and operating cash flow reached$347.4M , the profit jump was not just accounting noise; it translated into cash strong enough to clear long-term debt entirely.
With gross margin above
The balance sheet still shows negative equity, but that mostly reflects accumulated past losses rather than current borrowing strain because long-term debt was eliminated in FY2025. That cleanup cut total liabilities by about
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Biocryst Pharmaceuticals Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Biocryst Pharmaceuticals Inc has an operating margin of 39.0%, meaning the company retains $39 of operating profit per $100 of revenue. This results in a moderate score of 60/100, indicating healthy but not exceptional operating efficiency. This is up from -0.6% the prior year.
Biocryst Pharmaceuticals Inc's revenue surged 94.1% year-over-year to $874.8M, reflecting rapid business expansion. This strong growth earns a score of 96/100.
Biocryst Pharmaceuticals Inc's current ratio of 2.06 indicates adequate short-term liquidity, earning a score of 59/100. The company can meet its near-term obligations, though with limited headroom.
Biocryst Pharmaceuticals Inc converts 39.4% of revenue into free cash flow ($344.9M). This strong cash generation earns a score of 68/100.
Biocryst Pharmaceuticals Inc scores 2.62, placing it in the grey zone between 1.81 and 2.99. The score is driven primarily by a large market capitalization ($2.5B) relative to total liabilities ($633.3M). This signals moderate financial risk that warrants monitoring.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Biocryst Pharmaceuticals Inc passes 7 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Biocryst Pharmaceuticals Inc generates $1.32 in operating cash flow ($347.4M OCF vs $263.9M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Biocryst Pharmaceuticals Inc earns $4.32 in operating income for every $1 of interest expense ($341.0M vs $78.9M). This adequate coverage means the company can meet its interest obligations, but has limited cushion if earnings fall.
Key Financial Metrics
Earnings & Revenue
Biocryst Pharmaceuticals Inc generated $874.8M in revenue in fiscal year 2025. This represents an increase of 94.1% from the prior year.
Biocryst Pharmaceuticals Inc's EBITDA was $342.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 26497.7% from the prior year.
Biocryst Pharmaceuticals Inc reported $263.9M in net income in fiscal year 2025. This represents an increase of 396.9% from the prior year.
Biocryst Pharmaceuticals Inc earned $1.21 per diluted share (EPS) in fiscal year 2025. This represents an increase of 381.4% from the prior year.
Cash & Balance Sheet
Biocryst Pharmaceuticals Inc generated $344.9M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 749.0% from the prior year.
Biocryst Pharmaceuticals Inc held $89.7M in cash against $0 in long-term debt as of fiscal year 2025, with $196.1M of liabilities due within a year.
Not reported for fiscal year 2025.
Margins & Returns
Biocryst Pharmaceuticals Inc's gross margin was 97.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 0.5 percentage points from the prior year.
Biocryst Pharmaceuticals Inc's operating margin was 39.0% in fiscal year 2025, reflecting core business profitability. This is up 39.5 percentage points from the prior year.
Biocryst Pharmaceuticals Inc's net profit margin was 30.2% in fiscal year 2025, showing the share of revenue converted to profit. This is up 49.9 percentage points from the prior year.
Not reported for fiscal year 2025.
Capital Allocation
Biocryst Pharmaceuticals Inc invested $166.1M in research and development in fiscal year 2025. This represents a decrease of 4.9% from the prior year.
Biocryst Pharmaceuticals Inc invested $2.5M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 119.6% from the prior year.
Not reported for fiscal year 2025.
BCRX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $940.6M | $874.8M+94.1% | $450.7M+36.0% | $331.4M+22.4% | $270.8M+72.3% | $157.2M+782.4% | $17.8M-63.5% | $48.8M+136.5% | $20.7M-18.0% | $25.2M-4.4% | $26.4M-45.4% | $48.3M+254.6% | $13.6M-21.5% | $17.3M-34.1% | $26.3M+33.9% | $19.6M |
| Cost of Revenue | $20.9M | $19.1M+55.5% | $12.3M+173.8% | $4.5M-30.1% | $6.4M-11.4% | $7.2M+366.4% | $1.6M-58.4% | $3.7M | N/A | $1.1M-50.3% | $2.3M+67.9% | $1.4M+136700.0% | $1K | N/A | N/A | N/A |
| Gross Profit | $919.7M | $855.8M+95.2% | $438.4M+34.1% | $326.9M+23.6% | $264.4M+76.3% | $149.9M+822.0% | $16.3M-63.9% | $45.1M | N/A | $24.0M0.0% | $24.1M-48.7% | $46.9M+244.6% | $13.6M | N/A | N/A | N/A |
| R&D Expenses | $197.8M | $166.1M-4.9% | $174.6M-19.4% | $216.6M-14.5% | $253.3M+21.3% | $208.8M+69.8% | $123.0M+14.8% | $107.1M+26.1% | $84.9M+26.8% | $67.0M+9.8% | $61.0M-16.1% | $72.8M+40.5% | $51.8M+23.5% | $41.9M-14.7% | $49.2M-14.1% | $57.2M |
| SG&A Expenses | $337.3M | $348.6M+30.9% | $266.3M+24.4% | $214.1M+34.3% | $159.4M+34.1% | $118.8M+74.9% | $67.9M+83.0% | $37.1M+25.8% | $29.5M+111.8% | $13.9M+23.8% | $11.3M-13.8% | $13.0M+74.9% | $7.5M+24.2% | $6.0M-34.2% | $9.1M-23.8% | $12.0M |
| Operating Income | -$313.2M | $341.0M+13508.9% | -$2.5M+97.5% | -$103.7M+30.1% | -$148.4M+16.5% | -$177.7M-1.7% | -$174.8M-75.7% | -$99.5M-5.6% | -$94.2M-64.1% | -$57.4M-18.1% | -$48.6M-23.2% | -$39.4M+13.8% | -$45.8M-49.0% | -$30.7M+9.4% | -$33.9M+31.7% | -$49.6M |
| Interest Expense | $75.3M | $78.9M-19.9% | $98.5M-9.0% | $108.2M+9.2% | $99.1M+67.1% | $59.3M+308.9% | $14.5M+21.9% | $11.9M+29.6% | $9.2M+7.1% | $8.6M+32.0% | $6.5M+24.8% | $5.2M+4.0% | $5.0M+4.6% | $4.8M+2.4% | $4.7M+23.6% | $3.8M |
| Income Tax | $3.5M | $3.5M+83.2% | $1.9M+521.6% | $310K-88.7% | $2.7M+21.3% | $2.3M | $0 | $0 | $0 | $0 | $0 | $0-100.0% | $17.3M+102.1% | $8.6M+22.4% | $7.0M | N/A |
| Net Income | -$384.7M | $263.9M+396.9% | -$88.9M+60.8% | -$226.5M+8.3% | -$247.1M-34.3% | -$184.1M-0.7% | -$182.8M-67.9% | -$108.9M-7.6% | -$101.3M-53.9% | -$65.8M-19.3% | -$55.1M-28.2% | -$43.0M+4.8% | -$45.2M-50.1% | -$30.1M+23.0% | -$39.1M+31.4% | -$56.9M |
| EPS (Diluted) | — | $1.21+381.4% | -$0.43+63.6% | -$1.18+11.3% | -$1.33-29.1% | -$1.03+5.5% | -$1.09 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
BCRX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $514.2M+4.8% | $490.4M-5.1% | $517.0M-6.0% | $550.0M-6.5% | $588.2M+75.7% | $334.7M+91.0% | $175.3M+19.4% | $146.8M-17.6% | $178.3M+98.4% | $89.8M-26.6% | $122.4M-10.6% | $136.9M+180.1% | $48.9M-14.9% | $57.4M-30.1% | $82.2M |
| Current Assets | $404.3M-4.2% | $422.0M-14.9% | $496.0M-4.0% | $516.5M-8.8% | $566.1M+74.8% | $323.8M+97.0% | $164.3M+43.7% | $114.4M-8.8% | $125.4M+87.2% | $67.0M+5.0% | $63.8M-28.6% | $89.3M+112.1% | $42.1M+0.3% | $42.0M-20.6% | $52.9M |
| Cash & Equivalents | $89.7M-14.3% | $104.7M-5.4% | $110.6M-63.7% | $304.8M-39.6% | $504.4M+85.4% | $272.1M+138.3% | $114.2M+327.1% | $26.7M-46.8% | $50.3M+127.5% | $22.1M-23.5% | $28.9M-47.0% | $54.5M+157.7% | $21.2M+1.3% | $20.9M+27.0% | $16.4M |
| Inventory | $5.4M-33.3% | $8.1M-71.8% | $28.7M+4.2% | $27.5M+74.4% | $15.8M+124.3% | $7.0M | $0-100.0% | $1.6M | N/A | $500K-69.0% | $1.6M+136.0% | $683K-82.8% | $4.0M0.0% | $4.0M+1413.3% | $263K |
| Accounts Receivable | $106.8M+35.1% | $79.1M+38.8% | $57.0M+12.6% | $50.6M+72.0% | $29.4M+240.2% | $8.6M-61.0% | $22.1M+415.9% | $4.3M-29.8% | $6.1M-30.2% | $8.8M+40.4% | $6.2M | N/A | N/A | N/A | N/A |
| Total Liabilities | $633.3M-34.5% | $966.4M-0.6% | $972.5M+15.1% | $844.6M+21.5% | $695.1M+96.4% | $354.0M+158.3% | $137.0M+40.4% | $97.6M+3.3% | $94.5M+7.1% | $88.3M+18.3% | $74.6M+21.9% | $61.2M+22.5% | $50.0M-13.6% | $57.9M-14.1% | $67.4M |
| Current Liabilities | $196.1M+22.2% | $160.4M+6.9% | $150.0M+42.1% | $105.5M+1.7% | $103.7M-1.8% | $105.7M+14.4% | $92.3M+32.9% | $69.5M-7.2% | $74.8M+37.7% | $54.4M-12.7% | $62.3M+8.7% | $57.3M+275.5% | $15.3M-11.4% | $17.2M-34.5% | $26.3M |
| Long-Term Debt | $0-100.0% | $314.9M+3.8% | $303.2M+30.9% | $231.6M+70.2% | $136.1M+13.7% | $119.7M | N/A | $30.0M+30.4% | $23.0M0.0% | $23.0M | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$119.2M+75.0% | -$475.9M-4.5% | -$455.5M-54.6% | -$294.6M-175.4% | -$107.0M-455.4% | -$19.3M-150.4% | $38.3M-22.3% | $49.2M-41.2% | $83.8M+5208.4% | $1.6M-96.7% | $47.7M-36.9% | $75.6M+6817.1% | -$1.1M-148.0% | -$454K-103.1% | $14.8M |
| Retained Earnings | -$1.5B+14.9% | -$1.8B-5.3% | -$1.7B-15.6% | -$1.5B-20.5% | -$1.2B-18.0% | -$1.0B-21.7% | -$840.6M-14.8% | -$732.0M-15.8% | -$631.8M-11.6% | -$566.1M-10.8% | -$510.9M-9.2% | -$467.9M-10.7% | -$422.7M-7.7% | -$392.6M-11.1% | -$353.5M |
Not reported in any period shown, so not listed: Goodwill.
BCRX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $376.1M | $347.4M+767.8% | -$52.0M+45.3% | -$95.1M+41.2% | -$161.8M-13.9% | -$142.2M-5.2% | -$135.1M-50.8% | -$89.6M+3.2% | -$92.6M-125.0% | -$41.1M+23.0% | -$53.4M-307.4% | -$13.1M+66.0% | -$38.6M-45.3% | -$26.5M+29.1% | -$37.4M-16.0% | -$32.3M |
| Capital Expenditures | $2.8M | $2.5M+119.6% | $1.1M-48.2% | $2.2M+60.5% | $1.4M-43.4% | $2.4M+364.0% | $514K+49.9% | $343K-6.3% | $366K+11.6% | $328K-93.8% | $5.3M+3.0% | $5.1M+4732.1% | $106K+253.3% | $30K-73.5% | $113K+105.5% | $55K |
| Free Cash Flow | $373.4M | $344.9M+749.0% | -$53.1M+45.4% | -$97.3M+40.4% | -$163.2M-12.9% | -$144.5M-6.6% | -$135.6M-50.8% | -$89.9M+3.2% | -$92.9M-124.1% | -$41.5M+29.4% | -$58.7M-221.9% | -$18.2M+52.8% | -$38.7M-45.5% | -$26.6M+29.2% | -$37.5M-16.1% | -$32.3M |
| Investing Cash Flow | -$448.7M | -$13.7M-126.0% | $52.6M+140.0% | -$131.5M-2.5% | -$128.2M-911.4% | $15.8M+330.5% | -$6.9M-108.8% | $77.9M+1534.5% | $4.8M+107.4% | -$64.6M-377.8% | $23.3M+229.3% | -$18.0M | N/A | -$3.5M-113.9% | $24.9M+119.9% | $11.3M |
| Financing Cash Flow | $124.6M | -$349.9M-5974.1% | -$5.8M-117.7% | $32.5M-63.1% | $88.0M-75.5% | $359.7M+19.7% | $300.6M+203.3% | $99.1M+58.5% | $62.5M-53.9% | $135.7M+482.3% | $23.3M+325.3% | $5.5M | N/A | $30.3M+78.5% | $17.0M-28.6% | $23.8M |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $61K |
Not reported in any period shown, so not listed: Dividends Paid.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
BCRX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 97.8%+0.5pp | 97.3%-1.4pp | 98.7%+1.0pp | 97.6%+2.2pp | 95.4%+4.1pp | 91.3%-1.1pp | 92.4% | N/A | 95.5%+4.2pp | 91.3%-5.9pp | 97.2%-2.8pp | 100.0% | N/A | N/A | N/A |
| Operating Margin | 39.0%+39.5pp | -0.6%+30.7pp | -31.3%+23.5pp | -54.8% | -113.1% | -981.1% | -203.7% | -456.2% | -228.0% | -184.4% | -81.7% | -336.4% | -177.2% | -128.9% | -252.4% |
| Net Margin | 30.2%+49.9pp | -19.7%+48.6pp | -68.4%+22.9pp | -91.2% | -117.1% | -1026.4% | -223.0% | -490.3% | -261.2% | -209.2% | -89.1% | -332.1% | -173.7% | -148.6% | -289.9% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | -284.7%-79.0pp | -205.7%-127.1pp | -78.5%+3416.0pp | -3494.6%-3404.4pp | -90.1%-30.4pp | -59.8% | N/A | N/A | -384.6% |
| Return on Assets | 51.3%+69.4pp | -18.1%+25.7pp | -43.8%+1.1pp | -44.9%-13.6pp | -31.3%+23.3pp | -54.6%+7.5pp | -62.1%+6.8pp | -69.0%-32.0pp | -36.9%+24.5pp | -61.4%-26.2pp | -35.2%-2.1pp | -33.0%+28.6pp | -61.6%+6.4pp | -68.0%+1.2pp | -69.3% |
| Current Ratio | 2.06-0.6x | 2.63-0.7x | 3.31-1.6x | 4.90-0.6x | 5.46+2.4x | 3.06+1.3x | 1.78+0.1x | 1.650.0x | 1.68+0.4x | 1.23+0.2x | 1.02-0.5x | 1.56-1.2x | 2.76+0.3x | 2.44+0.4x | 2.01 |
| Debt-to-Equity | N/A | N/A | N/A | N/A | N/A | N/A | 3.58+3.0x | 0.61+0.3x | 0.27-14.3x | 14.58+13.0x | 1.56+0.8x | 0.81 | N/A | N/A | 4.55 |
| FCF Margin | 39.4%+51.2pp | -11.8%+17.6pp | -29.4%+30.9pp | -60.3%+31.7pp | -92.0% | -761.4% | -184.1% | -450.0% | -164.7% | -222.8% | -37.8% | -284.1% | -153.3% | -142.7% | -164.5% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Note: Shareholder equity is negative (-$119.2M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Similar Companies
Where Biocryst Pharmaceuticals Inc Ranks
Frequently Asked Questions
What is Biocryst Pharmaceuticals Inc's annual revenue?
Biocryst Pharmaceuticals Inc (BCRX) reported $874.8M in total revenue for fiscal year 2025. This represents a 94.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Biocryst Pharmaceuticals Inc's revenue growing?
Biocryst Pharmaceuticals Inc (BCRX) revenue grew by 94.1% year-over-year, from $450.7M to $874.8M in fiscal year 2025.
Is Biocryst Pharmaceuticals Inc profitable?
Yes, Biocryst Pharmaceuticals Inc (BCRX) reported a net income of $263.9M in fiscal year 2025, with a net profit margin of 30.2%.
What is Biocryst Pharmaceuticals Inc's EBITDA?
Biocryst Pharmaceuticals Inc (BCRX) had EBITDA of $342.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Biocryst Pharmaceuticals Inc have?
As of fiscal year 2025, Biocryst Pharmaceuticals Inc (BCRX) had $89.7M in cash and equivalents against $0 in long-term debt.
What is Biocryst Pharmaceuticals Inc's gross margin?
Biocryst Pharmaceuticals Inc (BCRX) had a gross margin of 97.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Biocryst Pharmaceuticals Inc's operating margin?
Biocryst Pharmaceuticals Inc (BCRX) had an operating margin of 39.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Biocryst Pharmaceuticals Inc's net profit margin?
Biocryst Pharmaceuticals Inc (BCRX) had a net profit margin of 30.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Biocryst Pharmaceuticals Inc's free cash flow?
Biocryst Pharmaceuticals Inc (BCRX) generated $344.9M in free cash flow during fiscal year 2025. This represents a 749.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Biocryst Pharmaceuticals Inc's operating cash flow?
Biocryst Pharmaceuticals Inc (BCRX) generated $347.4M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Biocryst Pharmaceuticals Inc's total assets?
Biocryst Pharmaceuticals Inc (BCRX) had $514.2M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Biocryst Pharmaceuticals Inc's capital expenditures?
Biocryst Pharmaceuticals Inc (BCRX) invested $2.5M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Biocryst Pharmaceuticals Inc spend on research and development?
Biocryst Pharmaceuticals Inc (BCRX) invested $166.1M in research and development during fiscal year 2025.
What is Biocryst Pharmaceuticals Inc's current ratio?
Biocryst Pharmaceuticals Inc (BCRX) had a current ratio of 2.06 as of fiscal year 2025, which is generally considered healthy.
What is Biocryst Pharmaceuticals Inc's return on assets (ROA)?
Biocryst Pharmaceuticals Inc (BCRX) had a return on assets of 51.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
Why is Biocryst Pharmaceuticals Inc's debt-to-equity ratio negative or not reported?
Biocryst Pharmaceuticals Inc (BCRX) has negative shareholder equity of -$119.2M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Biocryst Pharmaceuticals Inc's Altman Z-Score?
Biocryst Pharmaceuticals Inc (BCRX) has an Altman Z-Score of 2.62, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Biocryst Pharmaceuticals Inc's Piotroski F-Score?
Biocryst Pharmaceuticals Inc (BCRX) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Biocryst Pharmaceuticals Inc's earnings high quality?
Biocryst Pharmaceuticals Inc (BCRX) has an earnings quality ratio of 1.32x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Biocryst Pharmaceuticals Inc cover its interest payments?
Biocryst Pharmaceuticals Inc (BCRX) has an interest coverage ratio of 4.32x, meaning it can adequately cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Biocryst Pharmaceuticals Inc?
Biocryst Pharmaceuticals Inc (BCRX) scores 74 out of 100 on our Financial Health Score, indicating strong standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.